% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Vithayathil:275220,
      author       = {M. Vithayathil and A. D'Alessio and C. A. M. Fulgenzi and
                      N. Nishida and M. Schönlein and J. von Felden and K.
                      Schulze and H. Wege and A. Saeed and B. Wietharn and H.
                      Hildebrand and L. Wu and C. Ang and T. U. Marron and A.
                      Weinmann and P. R. Galle and D. Bettinger and B. Bengsch$^*$
                      and A. Vogel and L. Balcar and B. Scheiner and P.-C. Lee and
                      Y.-H. Huang and S. Amara and M. Muzaffar and A. R. Naqash
                      and A. Cammarota and V. Zanuso and T. Pressiani and M.
                      Pinter and A. Cortellini and M. Kudo and L. Rimassa and D.
                      J. Pinato and R. Sharma},
      title        = {{I}mpact of body mass index in patients receiving
                      atezolizumab plus bevacizumab for hepatocellular carcinoma.},
      journal      = {Hepatology international},
      volume       = {17},
      number       = {4},
      issn         = {1936-0533},
      address      = {Heidelberg},
      publisher    = {Springer},
      reportid     = {DKFZ-2023-00678},
      pages        = {904-914},
      year         = {2023},
      note         = {2023 Aug;17(4):904-914},
      abstract     = {Atezolizumab plus bevacizumab (Atezo/Bev) is first
                      line-treatment for unresectable hepatocellular carcinoma
                      (HCC). Body mass index (BMI) has demonstrated predictive
                      value for response to immunotherapy in non-HCC cancer types.
                      Our study investigated the effect of BMI on safety and
                      efficacy of real-life use of Atezo/Bev for unresectable
                      HCC.191 consecutive patients from seven centres receiving
                      Atezo/Bev were included in the retrospective study. Overall
                      survival (OS), progression-free survival (PFS), overall
                      response rate (ORR) and disease control rate (DCR) defined
                      by RECIST v1.1 were measured in overweight (BMI ≥ 25) and
                      non-overweight (BMI < 25) patients. Treatment-related
                      adverse events (trAEs) were evaluated.Patients in the
                      overweight cohort (n = 94) had higher rates of non-alcoholic
                      fatty liver disease (NAFLD) and lower rates of Hepatitis B
                      compared to non-overweight cohort (n = 97). Baseline
                      Child-Pugh class and Barcelona Clinic Liver Cancer stage
                      were similar between cohorts, with lower rates of
                      extrahepatic spread in the overweight group. Overweight
                      patients had similar OS compared to non-overweight (median
                      OS 15.1 vs. 14.9 months; p = 0.99). BMI did not influence
                      median PFS (7.1 vs. 6.1 months; p = 0.42), ORR $(27.2\%$ vs.
                      $22.0\%;$ p = 0.44) and DCR $(74.1\%$ vs. $71.9\%;$ p =
                      0.46). There were higher rates of atezolizumab-related
                      fatigue $(22.3\%$ vs. $10.3\%;$ p = 0.02) and
                      bevacizumab-related thrombosis $(8.5\%$ vs. $2.1\%;$ p =
                      0.045) in the overweight patients, but overall trAEs and
                      treatment discontinuation were comparable between
                      cohorts.Atezo/Bev has comparable efficacy in overweight HCC
                      patients, with an increase in treatment-related fatigue and
                      thrombosis. Combination therapy is safe and efficacious to
                      use in overweight patients, including those with underlying
                      NAFLD.},
      keywords     = {Anti-programmed death-ligand (Other) / Anti-vascular
                      endothelial growth factor (Other) / Checkpoint inhibitor
                      (Other) / Cirrhosis (Other) / Immunotherapy (Other) /
                      Non-alcoholic fatty liver disease (Other) / Obesity (Other)
                      / Overall survival (Other) / Overweight (Other) /
                      Progression-free survival (Other)},
      cin          = {FR01},
      ddc          = {610},
      cid          = {I:(DE-He78)FR01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37005953},
      doi          = {10.1007/s12072-023-10491-3},
      url          = {https://inrepo02.dkfz.de/record/275220},
}